Human prostaglandin reductases dearomatize and inactivate benzothiazinone antitubercular drugs

This study reveals that human prostaglandin reductases PTGR1 and PTGR2 inactivate the antitubercular drug macozinone by catalyzing its reductive dearomatization, a novel host-mediated metabolic pathway that can be inhibited to restore the drug's efficacy.

The Gist

The Story of the "Magic Bullet" and the "Hostile Host"

Imagine you have a very powerful magic bullet designed to kill a specific enemy: the bacteria that causes Tuberculosis (TB). This bullet is a drug called Macozinone (MCZ). It works by sneaking into the bacteria and jamming a critical machine inside them, causing the bacteria to fall apart and die. It's so good at this that scientists were very excited to bring it to human patients.

However, there was a mystery. When doctors gave this drug to humans, the drug seemed to get "neutralized" very quickly in the bloodstream. It wasn't just being broken down by the liver in the usual way; it was being transformed into a different chemical shape called H2MCZ.

For a long time, scientists didn't know who was doing the transforming or why. Was the drug turning into a "super-bullet" (a prodrug) that was even stronger? Or was it turning into a "dud" that couldn't kill the bacteria anymore?

The Detective Work: Finding the Culprit

The researchers in this paper acted like detectives. They knew the drug was being changed by an enzyme (a biological machine) inside the human body, but they didn't know which one.

1. The Wrong Suspects: They first checked the usual suspects: enzymes that usually break down drugs or fight off toxins. They checked the gut bacteria (thinking maybe the bacteria in our intestines were doing it), but that wasn't it. They checked the liver's standard detox machines, but those didn't seem to be the main culprits either.
2. The "Bodyguard" Turned Traitor: Finally, they looked at a group of enzymes called Prostaglandin Reductases (PTGR1 and PTGR2).
   • The Analogy: Think of these enzymes as the body's security guards. Their normal job is to patrol the bloodstream and neutralize "prostaglandins" (chemical messengers that cause inflammation and pain). Once the message is delivered, the security guard grabs the messenger, changes its shape, and turns it off so it stops shouting.
   • The Twist: The researchers discovered that Macozinone looks suspiciously similar to these prostaglandin messengers. The security guards (PTGR1 and PTGR2) saw the drug, thought, "Hey, that looks like a messenger I need to shut down," and grabbed it.
3. The Transformation: When the security guard grabbed the drug, it didn't just break it; it performed a specific chemical trick called dearomatization.
   • The Analogy: Imagine the drug is a rigid, flat, circular table (an aromatic ring). The security guard pushes a button that makes the table wobble and lose its perfect shape, turning it into a floppy, bent chair. This new shape is H2MCZ.

The Big Discovery: The "Dud" Bullet

Once they found the culprit, they had to answer the big question: Is the new shape (H2MCZ) better or worse than the original?

• The Theory: Some scientists thought the drug was a "prodrug," meaning the body needed to change it into H2MCZ to make it work. Like a key that needs to be bent slightly to fit a lock.
• The Reality: The researchers tested this and found the opposite.
  • The original drug (MCZ) is a sharp, lethal dart that kills TB bacteria efficiently.
  • The transformed drug (H2MCZ) is a soft, squishy sponge. It still exists in the blood, but it has lost most of its ability to kill the bacteria.

The Conclusion: The human body's own security guards (PTGR1 and PTGR2) are accidentally disarming the medicine. They are turning the lethal dart into a harmless sponge, which explains why the drug might not work as well as expected in humans compared to mice (mice don't have these specific guards as active).

The Solution: Blocking the Guards

If the security guards are the problem, can we stop them?

The researchers tested common painkillers and anti-inflammatories (like Diclofenac and Indomethacin). These drugs happen to also block the security guards (PTGR1/2).

• The Experiment: When they added these painkillers to the mix in a test tube, the security guards were busy and couldn't grab the TB drug.
• The Result: The TB drug stayed in its original, lethal "dart" shape and killed the bacteria much more effectively.

Why This Matters

This paper reveals a brand-new way our bodies handle medicine. Usually, we think of the liver as the place where drugs are broken down. This study shows that enzymes meant for inflammation and pain can accidentally sabotage antibiotics.

The Takeaway:
If we want Macozinone to work better against TB in humans, we might need to give it alongside a "bodyguard blocker" (like a specific painkiller) to keep the security guards from disarming the medicine. It's like hiring a bouncer to keep the security guards away from the VIP guest so the guest can do their job.

This is a huge step forward in understanding why some drugs work in mice but fail in humans, and it opens the door to smarter ways to treat Tuberculosis.

Technical Summary

1. Problem Statement

Macozinone (MCZ, PBTZ169) is a potent clinical-stage benzothiazinone drug targeting Mycobacterium tuberculosis by covalently inhibiting the essential enzyme DprE1. However, in humans and certain mammals, MCZ undergoes a unique metabolic transformation: reductive dearomatization to form a Hydride Meisenheimer Complex (H2MCZ).

• The Mystery: While H2MCZ is the major circulating metabolite in humans, the specific host enzyme responsible for this reaction was unknown.
• The Controversy: It was unclear whether H2MCZ was an inactive byproduct or a prodrug that retained (or enhanced) antimycobacterial activity. Previous hypotheses suggested H2MCZ might be the active species, but its high abundance in humans contrasted with the drug's efficacy in animal models where H2MCZ levels were low.

2. Methodology

The authors employed a multi-step approach combining enzymatic screening, recombinant protein studies, inhibitor profiling, and functional antimycobacterial assays.

• Enzymatic Screening:
  • Tested various biological fractions (cytosol, S9, microsomes, mitochondria) from pig and human tissues to localize the reductase activity.
  • Screened candidate enzyme families: Carbonyl reductases (CBR1, AKRs), redox homeostasis enzymes (NQO1, TrxR1, GR), nucleophilic aromatic substitution enzymes (GST), and $\alpha,\beta$-unsaturated ketone reductases.
  • Used LC-MS/MS to quantify H2MCZ formation.
• Inhibitor Profiling:
  • Tested prototypical inhibitors of various reductive pathways (e.g., dicumarol, curcumin, NSAIDs, gold compounds) in pig liver cytosol (PLC) to narrow down the enzyme class.
• Recombinant Enzyme Validation:
  • Incubated MCZ with pure recombinant human PTGR1 (Prostaglandin Reductase 1) and PTGR2 (Prostaglandin Reductase 2/ZADH1) to confirm direct catalysis.
  • Determined kinetic parameters ($K_m$, $V_{max}$) and inhibition constants ($IC_{50}$) for various inhibitors.
• Functional Activity Assays:
  • MIC Determination: Measured Minimum Inhibitory Concentrations (MIC) of MCZ, synthetic H2MCZ, and mixtures against M. tuberculosis and M. smegmatis.
  • DprE1 Inhibition: Assessed direct inhibition of purified DprE1 by MCZ vs. H2MCZ.
  • Pre-incubation Studies: Pre-incubated MCZ with PTGR2 (with and without inhibitors) before testing antimicrobial activity to simulate metabolic inactivation.
  • Ex Vivo Clinical Samples: Analyzed plasma/serum from human clinical trial volunteers (NCT03423030, NCT03776500) to correlate drug/metabolite levels with antimicrobial activity.

3. Key Contributions

• Identification of the Enzyme: The study definitively identifies PTGR1 and PTGR2 as the human enzymes responsible for the NADPH-dependent dearomatization of MCZ into H2MCZ. This is the first report of PTGR2 metabolizing a xenobiotic.
• Mechanistic Insight: The authors elucidate that MCZ possesses a "virtual" $\alpha,\beta$-unsaturated carbonyl motif (due to the electron-withdrawing effects of the nitro and trifluoromethyl groups) that mimics the natural substrate of PTGRs (15-keto-PGE2), allowing the enzyme to reduce the aromatic ring.
• Metabolic Inactivation Pathway: The paper establishes a novel host-mediated metabolic inactivation pathway where the host's own enzymes (involved in prostaglandin regulation) neutralize an antimicrobial drug.

4. Key Results

• Enzyme Specificity:
  • PTGR1 and PTGR2 catalyze the conversion of MCZ to p-H2MCZ (the specific isomer observed in vivo).
  • PTGR2 showed a three-fold higher yield of H2MCZ compared to PTGR1 under identical conditions.
  • Other candidates (NQO1, TrxR1, GST, CBR1) were ruled out.
• Inhibition:
  • The reaction is potently inhibited by dicumarol (IC50 ~0.06–0.33 µM), diclofenac, indomethacin, and the selective inhibitor PTGR2-IN-1.
• Antimicrobial Activity:
  • In Vitro: Synthetic H2MCZ showed slightly lower potency than MCZ against whole bacteria but was ~5-fold more potent than MCZ against purified DprE1. However, in whole-cell assays, H2MCZ was less active than MCZ.
  • Metabolic Inactivation: Pre-incubating MCZ with PTGR2 significantly increased the MIC (decreased activity) from ~1 µg/L to ~18 µg/L. Adding dicumarol during pre-incubation partially restored activity.
  • Ex Vivo: In human plasma samples, antimicrobial activity correlated strictly with MCZ concentrations, not H2MCZ levels. High H2MCZ levels did not correlate with bacterial killing.
• Conclusion on Mechanism: MCZ is not a prodrug. H2MCZ is a metabolic dead-end (or a reservoir that slowly re-oxidizes) that contributes to the loss of therapeutic efficacy in humans compared to animal models where this metabolism is less prominent.

5. Significance

• Novel Metabolic Mechanism: This study uncovers a previously unrecognized noncanonical enzymatic mechanism where host prostaglandin reductases (typically involved in lipid mediator regulation) metabolize and inactivate a xenobiotic antibiotic via aromatic ring dearomatization.
• Clinical Implications: The formation of H2MCZ in humans likely reduces the effective exposure of active MCZ, potentially explaining discrepancies in efficacy between preclinical models and human trials.
• Therapeutic Strategy: The findings suggest that co-administration of PTGR inhibitors (such as specific NSAIDs like diclofenac or indomethacin, or novel selective inhibitors) could block H2MCZ formation, thereby increasing the bioavailability and efficacy of benzothiazinone drugs.
• Drug Design: Future optimization of benzothiazinones should consider minimizing susceptibility to PTGR-mediated reduction, or conversely, exploiting this pathway for prodrug activation in specific contexts (though the current data suggests inactivation is the dominant effect).

In summary, the paper resolves a long-standing mystery regarding the metabolism of benzothiazinones, identifying PTGR1/2 as the culprits behind the drug's inactivation in humans and proposing a strategy to overcome this metabolic barrier.